Formulating Success: How Pharma Companies Engineer Around Expiring Drug Patents Before the Generic Cliff Hits
Every major drug company has a clock running in its boardroom. When a blockbuster patent expires, billions in annual revenue […]
How Drug Companies Build Patent Thickets Around Biologic Blockbusters (And How to Tear Them Down)
In 2002, AbbVie launched adalimumab—a monoclonal antibody for rheumatoid arthritis sold under the brand name Humira—at a price of roughly
AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay
Every pharmaceutical acquisition has a number at its core that almost nobody states plainly: the price you are paying for
AI Prior Art Search: How to Invalidate Key Drug Patents Before You Pay Read Post »
Russia’s VED & SSM Lists: How to Time Generic Entry Using Patent Expiration Data
The Market Nobody Reads Correctly Russia’s pharmaceutical market generated 2.85 trillion roubles in 2024, roughly $30.9 billion at prevailing exchange
Russia’s VED & SSM Lists: How to Time Generic Entry Using Patent Expiration Data Read Post »
Freedom to Operate in Pharma: The Step-by-Step FTO Analysis That Protects Your Pipeline
Every drug that reaches Phase III clinical trials carries two price tags: the cost of making it and the cost
Freedom to Operate in Pharma: The Step-by-Step FTO Analysis That Protects Your Pipeline Read Post »
Decoding Formulation Patents: How to Find Design-Around Opportunities Before Your Competitors Do
Every year, generic drug manufacturers pay hundreds of millions of dollars in settlements and delayed-entry agreements that, in hindsight, were
Beyond the ANDA: How to Use the 505(b)(2) Pathway to Build a Differentiated Drug—and Defend It
By the time a patent cliff arrives, most pharmaceutical companies have already lost the war. The moment generic manufacturers file
Russia Patent-Term Extensions: What Every Pharma IP Team Needs to Know Right Now
Russia is a $9.2 billion pharmaceutical market where the rulebook on intellectual property is being rewritten in real time. [1]
Russia Patent-Term Extensions: What Every Pharma IP Team Needs to Know Right Now Read Post »
Litigation-Aware Prosecution: Turn Your Drug Patent Portfolio Into a Competitive Assertion Asset
Prosecute to Win: Why Your Drug Patent Portfolio Is Your Next Competitive Assertion Asset The moment a generic manufacturer files
